He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

(Reuters) -Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday ...

Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $97 from $83 and keeps a Hold rating on the ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

The results from the PURPOSE 2 study, which builds on the 100% efficacy shown in PURPOSE 1, demonstrate lenacapavir's ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...